close

Login

Library
Shopping Cart
Remember Me
Forgot password/Login issues?
loading animation for AJAX calls
 
 
Direct (781) 489-7301,  Toll Free (866) 285-7215

Search

Search
BCC Advance Search

Global Markets for Generic Drugs

  • Published: January 2014
  • |
  • Report Code: PHM009G

REPORT HIGHLIGHTS

The global generics sector reached $269.8 billion in 2012. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.

This report provides:

  • An overview of the global market for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Examination of strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by “originator” companies to forestall generic competition.
  • Discussion of important trends by product categories and major country markets, acknowledging that Brazil, China, India, Mexico, and Russia are among the rising markets for generic activity.
  • Comprehensive profiles of leading generics companies, and updates on mergers and acquisitions.

SAMPLE FIGURE
MAJOR NATIONAL GENERIC MARKETS, THROUGH 2018
($ BILLIONS)
MAJOR NATIONAL GENERIC MARKETS, THROUGH 2018
To Contact us, click here  help


Source: BCC Research

Download Report Overview

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and a considered assessment of the regulatory environment, healthcare policies, demographics and other factors that directly affect the generic drug market. The wider economic environment is also taken into account.

The report examines strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by “originator” companies to forestall generic competition.

REASONS FOR DOING THE STUDY

  • This is a time of growth and change for the generic pharmaceutical sector. Major aspects that combine to create an opportunity for an up-to date market analysis include the following:
  • The demand for generics is increasing steadily because of pressure to control healthcare costs. At the same time fierce price competition in this area has put some companies in difficulties because of slashed profit margins. The main result has been a wave of M&A activity, and the rise of “supergenerics” offering added value as well as low prices. Not all traditional companies are positioned to exploit this trend.
  • A major growth driver for the generics sector is the fact that several blockbuster pharmaceutical brands are coming off-patent and are therefore open to generic competition — the phenomenon widely known as the “patent cliff.” But the originator companies are deploying formidable strategies to protect their franchise, including marketing their own branded generics.
  • With first-generation biopharmaceutical products reaching the end of their patent lives, a whole new market field — biogenerics, or biosimilars — is opening up for those generics companies capable of (or prepared to buy in) the technological expertise required.
  • The international landscape is changing for generics as for all pharmaceuticals. China, India, Russia, Mexico and Brazil are among rising centers of generic activity.

SCOPE OF REPORT

This report discusses the implications of all the above-mentioned trends, in the context of the current size and growth of the generics market, both in global terms and analyzed by the most important national markets. The nature and structure of the generics industry is discussed, with profiles of the leading 20-plus generics companies, and an update on mergers and acquisitions (M&A) activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

MARKET ANALYSES AND FORECASTS

Market figures are based on revenues at the manufacturer level and are projected on the basis of 2011-dollar value without attempting to predict the effect of inflation/deflation.

Therapeutic categories quantified and forecast include antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g. hypolipidaemics and antihypertensives) and drugs for respiratory conditions including asthma and COPD.

METHODOLOGY

Primary research includes interviews with leading individuals in generics companies, industry associations and regulatory bodies. Primary sources of published data include company annual reports, SEC filings, and government and industry publications. Secondary sources consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC.

INTENDED AUDIENCE

This report is designed to satisfy the information needs of a wide variety of individuals involved in the generics marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.

INFORMATION SOURCES

Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant trade associations such as the Generic Pharmaceutical Association (GPhA) and the European Generic Medicines Association (EGA).

ANALYST CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of two previous reports on the generics marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

BCC RESEARCH ONLINE SERVICES

BCC Research offers an online information retrieval service. Its home page, located at www.bccresearch.com, enables readers to:

  • Examine the complete BCC Research catalog of market research reports and place direct orders.
  • Read announcements of recently published reports.
  • Register for its well-known conferences.
  • Request additional information on any BCC Research product.
  • Take advantage of special offers.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

Download Report Overview

REPORT TOC

download table of contents
Pricing on the website is provided for single users and 2-5 users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at (+1)781-489-7301 or send an email to information@bccresearch.com
  Title/Chapter Name Pages Price
Global Markets for Generic Drugs 197 $6650
Chapter- 1: INTRODUCTION - Complimentary 3 $0
  Show Details
Chapter- 2: SUMMARY 3 $250
  Show Details
Chapter- 3: OVERVIEW 6 $304
  Show Details
Chapter- 4: THE NEW GENERICS ERA 16 $810
  Show Details
Chapter- 5: MAJOR GENERIC ISSUES 18 $911
  Show Details
Chapter- 6: THE GENERIC MARKET 24 $1215
  Show Details
Chapter- 7: THE GLOBAL GENERICS INDUSTRY 5 $253
  Show Details
Chapter- 8: PROFILES OF TOP TEN GENERICS COMPANIES 20 $1013
  Show Details
Chapter- 9: OTHER INTERNATIONAL GENERICS COMPANIES 29 $1468
  Show Details
Chapter- 10: THE AMERICAN REGION 25 $1266
  Show Details
Chapter- 11: THE ASIAN REGION 22 $1114
  Show Details
Chapter- 12: THE EUROPEAN REGION 26 $1316
  Show Details
 
  List of Tables
  List of Figures
Recommended combos for Forecast Model
+

BCC Research Report

Price: $6650

=

Total Price: $12150

Combo Price: $9500

Discount will be applied automatically after you will add the forecast model and any report to your cart.

 
Select License type:
buy now
downlaod report overview
Want to find out more
about this report?
request more info
Get Notified
on all the latest research reports
Subscribe

Choose your License

loading animation for AJAX calls